(GBLB) Groep Brussel Lambert - Ratings and Ratios

Groupe Bruxelles Lambert SA is a Belgium-based investment holding company with a diversified portfolio spanning industrial, consumer goods, and business services sectors. The company operates through six core segments: Imerys, a global leader in mineral-based specialty solutions; Canyon, a manufacturer of bicycles and related accessories; Affidea, a European provider of diagnostic imaging and cancer treatment services; Sanoptis, a medical and industrial optics company; and GBL Capital and Sienna Investment Managers, which focus on asset management and financial investments. Established in 1902, GBL is headquartered in Brussels, Belgium, and maintains a significant presence in European, North American, and international markets.

Based on the provided technical and fundamental data, GBLB is expected to experience moderate price fluctuations over the next three months. The stock is currently trading above its 20-day and 50-day moving averages (SMA 20: 68.25, SMA 50: 68.65) but below its 200-day moving average (SMA 200: 67.53), indicating near-term bullish momentum but longer-term bearish trends. The average true range (ATR) of 1.57 suggests relatively low volatility. Fundamentally, GBLB’s high P/E ratio (71.72) and low P/B ratio (0.60) signal a potentially overvalued stock with limited book value support. The forward P/E is not available, which may reflect uncertainty about future earnings. With a market cap of 8,529.48M EUR and a P/S ratio of 1.28, GBLB is positioned as a large-cap stock with moderate revenue multiple. The return on equity (RoE) of 0.94% indicates subpar profitability compared to industry peers. Over the next three months, GBLB may see a slight upward movement in price due to short-term technical strength, but the high valuation multiples and weak RoE could lead to a correction in the medium term.